Anti-Influenza Activity of C60 Fullerene Derivatives

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Shoji, Masaki ^a   Takahashi, Etsuhisa ^b   Hatakeyama, Dai ^a   Iwai, Yuma ^a   Morita, Yuka ^a   Shirayama, Riku ^a   Echigo, Noriko ^a   Kido, Hiroshi ^b   Nakamura, Shigeo ^c   Mashino, Tadahiko ^d   Okutani, Takeshi ^a   Kuzuhara, Takashi ^a  

^a TOKUSHIMA BUNRI UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

^c NIPPON MEDICAL SCHOOL   (Japan)

^d KEIO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1 CARBOXYMETHYL [60]FULLERENOPYRROLIDINE 2,5 DICARBOXYLIC ACID; 1 ETHOXYCARBONYLMETHYL[60]FULLERENOPYRROLIDINE 2,5 DICARBOXYLIC ACID 2 ETHYL ESTER; 1 ETHYL[60]FULLERENOPYRROLIDINE 2,5 DICARBOXYLIC ACID; 1,1,19,19 TETRAMETHYL [60]FULLERENODIPYRROLIDINIUM DIIODIDE; 1,4 DIHYDRO 6,7 DIHYDROXY[60]FULLERENONAPHTHLENE; 4 (19-METHYL[60]FULLERENOPYRROLIDIN 29 YL) 1 METHYLPYRIDINIUM IODIDE; 5 ISOPROPYL[60]FULLERENOPYRROLIDINE 2 CARBOXYLIC ACID; 5-PHENYL [60]FULLERENOPYRROLIDINE 2 CARBOXYLIC ACID; [60]FULLERENODICYCLOPROPANE 1,1,19,19 TETRACARBOXYLIC ACID; [60]FULLERENOPIPERAZINE 1,4 DIACETIC ACID; [60]FULLERENOPYRROLIDINE 2,5 DICARBOXYLIC ACID; [60]FULLERENOTRICYCLOPROPANE 1,1,19,19,199,199 HEXACARBOXYLIC ACID; ANTIVIRUS AGENT; FULLERENE DERIVATIVE; NONSTRUCTURAL PROTEIN 1; UNCLASSIFIED DRUG; VIRUS NUCLEOPROTEIN;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG SCREENING; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; IN VITRO STUDY; INFLUENZA A (H1N1); INFLUENZA A (H2N2); INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; MOLECULAR DOCKING; NONHUMAN; PROTEIN EXPRESSION;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; DOGS; ENZYME ACTIVATION; FULLERENES; INFLUENZA A VIRUS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; MOLECULAR CONFORMATION; MOLECULAR DOCKING SIMULATION; RNA REPLICASE; VIRAL PROTEINS;

AVIAN INFLUENZA VIRUS; INFLUENZA A VIRUS; SUIDAE;

EID: 84878968812     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0066337     Document Type: Article

References (44)

1. Taubenberger JK, Reid AH, Lourens RM, Wang R, Jin G, et al. (2005) Characterization of the 1918 influenza virus polymerase genes. Nature 437: 889-893.
2. Horimoto T, Kawaoka Y, (2005) Influenza: lessons from past pandemics, warnings from current incidents. Nat Rev Microbiol 3: 591-600.
3. Hatta M, Gao P, Halfmann P, Kawaoka Y, (2001) Molecular basis for high virulence of Hong Kong H5N1 influenza A viruses. Science 293: 1840-1842.
4. Itoh Y, Shinya K, Kiso M, Watanabe T, Sakoda Y, et al. (2009) In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 460: 1021-1025.
5. Neumann G, Noda T, Kawaoka Y, (2009) Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature 459: 931-939.
6. De Clercq E, (2006) Antiviral agents active against influenza A viruses. Nat Rev Drug Discov 5: 1015-1025.
7. Hayden FG, Atmar RL, Schilling M, Johnson C, Poretz D, et al. (1999) Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med 341: 1336-1343.
8. Collins PJ, Haire LF, Lin YP, Liu J, Russell RJ, et al. (2008) Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants. Nature 453: 1258-1261.
9. Reece PA, (2007) Neuraminidase inhibitor resistance in influenza viruses. J Med Virol 79: 1577-1586.
10. Honda A, Ishihama A, (1997) The molecular anatomy of influenza virus RNA polymerase. Biol Chem 378: 483-488.
11. Honda A, Mizumoto K, Ishihama A, (2002) Minimum molecular architectures for transcription and replication of the influenza virus. Proc Natl Acad Sci U S A 99: 13166-13171.
12. Kuzuhara T, Iwai Y, Takahashi H, Hatakeyama D, Echigo N, (2009) Green tea catechins inhibit the endonuclease activity of influenza A virus RNA polymerase. PLoS Curr Oct. 13 1: RRN1052.
13. Dias A, Bouvier D, Crépin T, McCarthy AA, Hart DJ, et al. (2009) The cap-snatching endonuclease of influenza virus polymerase resides in the PA subunit. Nature 458: 914-918.
14. Yuan P, Bartlam M, Lou Z, Chen S, Zhou J, et al. (2009) Crystal structure of an avian influenza polymerase PA(N) reveals an endonuclease active site. Nature 458: 909-913.
15. Iwai Y, Takahashi H, Hatakeyama D, Motoshima K, Ishikawa M, et al. (2010) Anti-influenza activity of phenethylphenylphthalimide analogs derived from thalidomide. Bioorg Med Chem 18: 5379-5390.
16. Iwai Y, Murakami K, Gomi Y, Hashimoto T, Asakawa Y, et al. (2011) Anti-influenza activity of marchantins, macrocyclic bisbibenzyls contained in liverworts. PLoS One 6: e19825.
17. Kuzuhara T, Kise D, Yoshida H, Horita T, Murazaki Y, et al. (2009) Structural basis of the influenza A virus RNA polymerase PB2 RNA-binding domain containing the pathogenicity-determinant lysine 627 residue. J Biol Chem 284: 6855-6860.
18. Kroto HW, Heath JR, O'Brien SC, Curl RF, Smalley RE, (1985) C60: Buckminsterfullerene. Nature 318: 162-163.
19. Sukeguchi D, Singh SP, Reddy MR, Yoshiyama H, Afre RA, et al. (2009) New diarylmethanofullerene derivatives and their properties for organic thin-film solar cells. Beilstein J Org Chem 24: 5-7.
20. Nakamura S, Mashino T, (2012) Water-soluble fullerene derivatives for drug discovery. J Nippon Med Sch 79: 248-254.
21. Bosi S, Da Ros T, Spalluto G, Prato M, (2003) Fullerene derivatives: an attractive tool for biological applications. Eur J Med Chem 38: 913-923.
22. Mashino T, Shimotohno K, Ikegami N, Nishikawa D, Okuda K, et al. (2005) Human immunodeficiency virus-reverse transcriptase inhibition and hepatitis C virus RNA-dependent RNA polymerase inhibition activities of fullerene derivatives. Bioorg Med Chem Lett 15: 1107-1109.
23. Nishizawa C, Hashimoto N, Yokoo S, Funakoshi-Tago M, Kasahara T, et al. (2009) Pyrrolidinium-type fullerene derivative-induced apoptosis by the generation of reactive oxygen species in HL-60 cells. Free Radic Res 43: 1240-1247.
24. Mashino T, Nishikawa D, Takahashi K, Usui N, Yamori T, et al. (2003) Antibacterial and antiproliferative activity of cationic fullerene derivatives. Bioorg Med Chem Lett 13: 4395-4397.
25. Okuda K, Mashino T, Hirobe M, (1996) Superoxide radical quenching and cytochrome c peroxidase-like activity of C60-dimalonic acid, C64(COOH)4. Bioorg Med Chem Lett 6: 539-542.
26. Noble E, Cox A, Deval J, Kim B, (2012) Endonuclease substrate selectivity characterized with full-length PA of influenza A virus polymerase. Virology 433: 27-34.
27. DuBois RM, Slavish PJ, Baughman BM, Yun MK, Bao J, et al. (2012) Structural and biochemical basis for development of influenza virus inhibitors targeting the PA endonuclease. PLoS Pathog 8: e1002830.
28. Chemical Computing Group C (2004) Molecular Operative Environment (MOE) 0707.
29. Zhao C, Lou Z, Guo Y, Ma M, Chen Y, et al. (2009) Nucleoside monophosphate complex structures of the endonuclease domain from the influenza virus polymerase PA subunit reveal the substrate binding site inside the catalytic center. J Virol 83: 9024-9030.
30. Tokuyama H, Ymago S, Nakamura E, (1993) Photoinduced biochemical activity of fullerene carboxylic acid. J Am Chem Soc 115: 7918-7919.
31. Furuta Y, Takahashi K, Kuno-Maekawa M, Sangawa H, Uehara S, et al. (2005) Mechanism of action of T-705 against influenza virus. Antimicrob Agents Chemother. 49: 981-986.
32. Li L, Chang S, Xiang J, Li Q, Liang H, et al. (2012) Screen anti-influenza lead compounds that target the PA(C) subunit of H5N1 viral RNA polymerase. PLoS One. 7: e35234.
33. Cianci C, Gerritz SW, Deminie C, Krystal M (2012) Influenza nucleoprotein: promising target for antiviral chemotherapy. Antivir Chem Chemother. 10.3851/IMP2235.
34. Ishikawa Y, Fujii S, (2011) Binding mode prediction and inhibitor design of anti-influenza virus diketo acids targeting metalloenzyme RNA polymerase by molecular docking. Bioinformation. 6: 221-225.
35. Nakazawa M, Kadowaki SE, Watanabe I, Kadowaki Y, Takei M, et al. (2008) PA subunit of RNA polymerase as a promising target for anti-influenza virus agents. Antiviral Res. 78: 194-201.
36. Tado M, Abe T, Hatta T, Ishikawa M, Nakada S, et al. (2001) Inhibitory effect of modified 5′-capped short RNA fragments on influenza virus RNA polymerase gene expression. Antivir Chem Chemother. 12: 353-358.
37. Nakamura Y, Oda K, Nakada S, (1991) Growth complementation of influenza virus temperature-sensitive mutants in mouse cells which express the RNA polymerase and nucleoprotein genes. J Biochem 110: 395-401.
38. Mullis KB, Faloona FA, (1987) Specific synthesis of DNA in vitro via a polymerase-catalyzed chain reaction. Methods Enzymol 155: 335-350.
39. Studier FW, Moffatt BA, (1986) Use of bacteriophage T7 RNA polymerase to direct selective high-level expression of cloned genes. J Mol Biol 189: 113-130.
40. Janknecht R, de Martynoff G, Lou J, Hipskind RA, Nordheim A, et al. (1991) Rapid and efficient purification of native histidine-tagged protein expressed by recombinant vaccinia virus. Proc Natl Acad Sci U S A 88: 8972-8976.
41. Anderson D, Harris R, Polayes D, Ciccarone V, Donahue R, et al. (1996) Rapid generation of recombinant baculoviruses and expression of foreign genes using the Bac-to-Bac® baculovirus expression system. Focus 17: 53-58.
42. Morris GM, Goodsell DS, Halliday RS, Huey R Hart WE, et al. (1998) Automated docking using Lamarckian genetic algorithm and an empirical binding free energy function. J Comp Chem 19: 1639-1662.
43. Goto J, Kataoka R, (2008) ASEDock-docking based on alpha spheres and excluded volumes. J Chem Inf Model 48: 583-590.
44. Takahashi E, Kataoka K, Indalao IL, Konoha K, Fujii K, et al. (2012) Oral clarithromycin enhances airway immunoglobulin A (IgA) immunity through induction of IgA class switching recombination and B-cell-activating factor of the tumor necrosis factor family molecule on mucosal dendritic cells in mice infected with influenza A virus. J Virol 86: 10924-10934.